Stereotactic Radiosurgery for Residual and Recurrent Nonfunctioning Pituitary Adenomas: A Contemporary Case Series of GammaKnife and CyberKnife Radiosurgery

• Published in: World neurosurgery 2020-11, Vol.143, p.e60-e69
• Main Authors: Tucker, Douglass, Penn, Marisa, Brunswick, Andrew, Uttarwar, Vedang, Gogia, Angad, Marietta, Michael, Yu, Cheng, Carmichael, John, Chang, Eric, Zada, Gabriel
• Format: Article
• Language: English
• Subjects: Adenoma - pathology; Adenoma - radiotherapy; Adult; Aged; Aged, 80 and over; CyberKnife; Female; GammaKnife; Hormone Replacement Therapy; Humans; Hypopituitarism - drug therapy; Hypopituitarism - epidemiology; Male; Middle Aged; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - radiotherapy; Neoplasm, Residual; Nonfunctional; Pituitary adenoma; Pituitary Neoplasms - pathology; Pituitary Neoplasms - radiotherapy; Progression-Free Survival; Radiosurgery; Radiosurgery - methods; Retrospective Studies; Tumor Burden
• ISSN: 1878-8750; 1878-8769
• DOI: 10.1016/j.wneu.2020.06.191

In patients with residual or recurrent nonfunctioning pituitary adenomas (NFPAs) after transsphenoidal resection, both GammaKnife (GKRS) and CyberKnife (CKRS) stereotactic radiosurgery (SRS) are viable treatment options. We report a retrospective single center series comparing assessing the effectiveness and complications from of these 2 commonly used SRS techniques. A total of 53 patients with prior surgical resection and residual or recurrent NFPAs who underwent GKRS or CKRS and minimum 3-month follow-up between January 2002 and February 2017 at a single center were identified. A total of 34 patients underwent GKRS and 19 received CKRS. CKRS patients had a larger maximal tumor diameter (P = 0.005) and tumor volume treated (P = 0.001). Differences between GKRS and CKRS treatment parameters included target volume, target volume treated, prescribed dose, maximum dose, prescription isodose line, and conformity index (P < 0.05). The mean follow-up time was 53.74 months for GKRS and 41.48 months for CKRS patients. Tumor progression developed in 6% of cases after GKRS versus 5% after CKRS. The mean progression-free survival was 48.44 months after GKRS and 38.57 months after CKRS (P = 0.61). Five-year actuarial tumor control rates were 91% after GKRS versus 89% after CKRS (P > 0.99). There were no differences in worsened vision or rates of hypopituitarism. In patients undergoing single fraction GKRS versus fractionated CKRS for NFPAs, both modalities had similar rates of tumor control, new hypopituitarism, and visual morbidity despite varying indications. This study validates the versatile use of these 2 SRS modalities for patients meeting their relative criteria, especially based on proximity to the optic apparatus and normal pituitary gland.